
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| respiratory tract diseases | D012140 |
| nervous system diseases | D009422 |
Brand Name | Status | Last Update |
|---|---|---|
| atovaquone | ANDA | 2025-11-07 |
| atovaquone and proguanil hcl | NDA authorized generic | 2023-10-23 |
| atovaquone and proguanil hydrochloride | ANDA | 2024-07-01 |
| atovaquone and proguanil hydrochloride atovaquone and proguanil hydrochloride pediatric | ANDA | 2019-12-31 |
| atovaquone oral suspension | ANDA | 2024-02-15 |
| malarone | New Drug Application | 2023-11-14 |
| mepron | New Drug Application | 2023-07-20 |

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Malaria | D008288 | EFO_0001068 | B54 | 1 | — | — | — | — | 1 |
| Drug common name | Atovaquone |
| INN | atovaquone |
| Description | Atovaquone is a naphthoquinone compound having a 4-(4-chlorophenyl)cyclohexyl group at the 2-position and a hydroxy substituent at the 3-position. It has a role as an antimalarial, an antifungal agent, an EC 1.3.5.2 [dihydroorotate dehydrogenase (quinone)] inhibitor, an EC 1.6.5.3 [NADH:ubiquinone reductase (H(+)-translocating)] inhibitor and an EC 1.10.2.2 (quinol--cytochrome-c reductase) inhibitor. It is a member of monochlorobenzenes and a hydroxy-1,4-naphthoquinone. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | O=C1C(O)=C([C@H]2CC[C@H](c3ccc(Cl)cc3)CC2)C(=O)c2ccccc21 |
| PDB | — |
| CAS-ID | 95233-18-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1450 |
| ChEBI ID | 575568 |
| PubChem CID | 74989 |
| DrugBank | DB01117 |
| UNII ID | Y883P1Z2LT (ChemIDplus, GSRS) |








